Diamond Equity Predicts MAIA Biotechnology Q1 Earnings

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) – Equities researchers at Diamond Equity issued their Q1 2026 earnings per share (EPS) estimates for MAIA Biotechnology in a research note issued to investors on Tuesday, March 25th. Diamond Equity analyst H. Diamond forecasts that the company will earn ($0.18) per share for the quarter. The consensus estimate for MAIA Biotechnology’s current full-year earnings is ($1.30) per share. Diamond Equity also issued estimates for MAIA Biotechnology’s Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.16) EPS, Q4 2026 earnings at ($0.13) EPS and FY2026 earnings at ($0.69) EPS.

MAIA Biotechnology Trading Down 6.0 %

MAIA stock opened at $1.57 on Wednesday. The firm has a fifty day moving average price of $1.87. MAIA Biotechnology has a 12-month low of $1.46 and a 12-month high of $5.99. The firm has a market capitalization of $41.07 million, a price-to-earnings ratio of -1.14 and a beta of 0.20.

Institutional Investors Weigh In On MAIA Biotechnology

A number of large investors have recently bought and sold shares of the stock. XTX Topco Ltd bought a new position in shares of MAIA Biotechnology in the 3rd quarter worth $31,000. Jane Street Group LLC bought a new position in shares of MAIA Biotechnology during the 4th quarter worth approximately $77,000. Finally, Geode Capital Management LLC grew its stake in MAIA Biotechnology by 22.9% in the 3rd quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock valued at $541,000 after purchasing an additional 35,821 shares during the period. 5.65% of the stock is currently owned by institutional investors and hedge funds.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.